ArticleTranslational neuroscience2025
Epigallocatechin gallate mitigates the motor deficits in a rotenone-induced Parkinson's disease rat model via promoting protein kinase D1 and inhibiting neuronal Parthanatos.
Article in Translational neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Epigenetic regulators polyphenols in neurodegenerative diseases: a promising intervention strategy.Annals of medicine · 2026Review
- Modulation of Behavioral, Biochemical, Immunomodulatory, and Transcriptional Profiles by the StrainInternational journal of molecular sciences · 2025Article
- Clinical insights into catechin-based nanomedicine: a review of therapeutic potential in neurodegenerative diseases.3 Biotech · 2025Review
- The neuroprotective effects of Dexmedetomidine: key mechanisms focusing on neuronal programmed cell death.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD), a neurodegenerative disorder characterized by degeneration of the dopaminergic (DA) neurons, is still lack of available treatments to completely block neurodegeneration. (-)-Epigallocatechin-3-gallate (EGCG), a predominant active polyphenol generated from green tea, exerts multiple neuroprotective roles in the nervous system. However, the function role of EGCG in PD and the underlying mechanism remains to be investigated. In the current study, we used the rotenone injection to build the PD rat model, followed by the EGCG treatment and determined by the behavior tests, measurements of malondialdehyde, glutathione, and superoxide dismutase levels, and enzyme-linked immunosorbent assay. We revealed that, in PD rats, EGCG upregulates protein kinase D1 (PKD1) and inhibits Parthanatos to ameliorate the impaired motor function, reduce the expression of tyrosine hydroxylase, suppress the oxidative stress, and suppress the inflammation in substantia nigra. These combined results suggest that EGCG can suppress oxidative stress and inflammation to prevent DA neuron degeneration to prevent rotenone-induced motor impairments, laying the foundation for EGCG to be a novel candidate for the treatment of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.